The drug, known scientifically as ticagrelor, was approved by the FDA in 2011 despite widespread pushback from scientists over concerns about its trial results. Since then, a number of studies ...

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring strokes.

Nevertheless, the new sub-analysis could provide a significant boost for Brilinta, as the data suggest treating patients for longer with the drug can prevent more from suffering a second ...

An investigation published in The BMJ raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the ...